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Abstract
Background: Peritoneal carcinomatosis from a gastrointestinal carcinoid tumour is rare and the
long-term management and prognosis have not been clearly defined. The natural history is different
from gastrointestinal adenocarcinoma, although its capacity to invade regional lymph nodes and
generate distal metastasis can make the management more complex. Whilst the development of
carcinomatosis is uncommonly reported, it may be higher than expected.
Case presentation: A 63 years-old woman underwent emergency surgery in 1993 for right iliac
fossa pain and a mass that was found to be an ileal carcinoid tumour. Over the next ten years,
further surgery was required for disseminated disease with peritoneal carcinomatosis and liver
metastasis. Systemic chemotherapy had little effect, although Somatostatin was used effectively to
relieve symptoms caused by the disseminated disease (flushing and diarrhoea).
Conclusion: Peritoneal carcinomatosis from carcinoid tumours is not well documented in the
literature. Aggressive surgery must be performed in order to control the disease since
chemotherapy has not been reported to be effective. With repeated surgery long-term survival can
be achieved in these patients.
Background
Intestinal carcinoid tumours can be found in all parts of
the gastrointestinal tract, with the highest incidence being
in the distal ileum. They present as a spectrum from small
'benign' tumours to the classical 'carcinoid syndrome' of
local tumour invasion with liver metastases and systemic
symptoms. However, compared to adenocarcinoma, they
have a better prognosis and long-term survival is reported.
This case reports peritoneal dissemination of the carci-
noid tumour and a long follow up of the disease.
Case presentation
A 63-year old woman presented in 1993 with a short his-
tory of right iliac fossa pain, localised peritonitis, and an
elevated white cell count. She reported a two-year history
of intermittent colicky abdominal pain. At operation, a 5
cm ileal tumour was found, situated 10 cm proximal from
the ileocaecal valve. This was resected. Histopathological
assessment confirmed a carcinoid tumour with locally
involved nodes (three positive lymph nodes). Nine years
later, she re-presented with right-sided abdominal pain, a
two-week history of diarrhoea, and a two month history
of episodes of her face getting "hot and blushing". A com-
puted tomography (CT) scan revealed a liver nodule (30
mm diameter) and a mass (60 × 40 mm) in the right iliac
fossa, which was in contact with a small intestinal loop
(Figure 1). Octreotide scanning (indium-111 labelled
pentreotide scintigraphy) demonstrated that the liver, the
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ascending colon, the right iliac fossa, and an area in the
superior half abdomen had positive foci (Figure 2). In
addition, the tumour marker CA-125 was raised (40.5 U/
ml)) and so were the urine levels of 5-hydroxyindoleacetic
acid (5-HIAA) (41.2 mg/day). Percutaneous biopsy of the
liver lesion confirmed a carcinoid tumour.
At operation in January 2003, peritoneal carcinomatosis
was discovered with tumoural implants over the greater
omentum, the parietal peritoneum, the left ovary, the ter-
minal ileum (with stenotic and fibrous lesion), and a liver
metastasis in segment IV. The peritoneal deposits, left
ovary and fallopian tube, the involved distal ileum, and
the liver metastasis were surgically removed. All deposits
were histologically metastases from the original carcinoid
tumour, although the distal ileal tumour metastasis only
affected the serosal and muscular layers. Following an
uneventful postoperative recovery, she commenced six
cycles of chemotherapy with Streptozotocine and 5-fluor-
ouracil.
In October 2004, she was admitted with abdominal
cramps and vomiting. A CT scan revealed dilated intesti-
nal loops that appeared to be attached to each other and
with the anterior abdominal wall. In view of the previous
surgery and the history of carcinomatosis, she underwent
a further laparotomy. However, at operation, the cause
Octreotide scanning of the patient revealed 'hot-spots' in the  liver (arrow), ascending colon, the right iliac fossa and upper  abdomen Figure 2
Octreotide scanning of the patient revealed 'hot-spots' in the 
liver (arrow), ascending colon, the right iliac fossa and upper 
abdomen.
The initial CT scan demonstrates a mass in the right iliac  fossa (arrow) and a suspected metasasis in segment IV of the  liver Figure 1
The initial CT scan demonstrates a mass in the right iliac 
fossa (arrow) and a suspected metasasis in segment IV of the 
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was adhesional obstruction, although some foci were
found in the parietal peritoneum and in the Pouch of
Douglas. These implants were less than 4 mm in length
and were excised. All the biopsies were positive for carci-
noid tumour and after an uneventful recovery she was dis-
charged. Further therapy with Somatostatin with the aim
to control the progression of the disease and because she
reported occasional flushing, achieved a good quality of
life. At review in March of 2006, the patient reported some
abdominal pain and infrequent flushing, but is otherwise
well. A further Octreotide scan revealed no disease activ-
ity.
Discussion
The first reported case of a carcinoid tumour was pub-
lished in 1888, but the molecular basis of the syndrome
was not elucidated until 1954 and the following year the
presence of serotonin was confirmed [1]. The serotonin
secreting cells have particular histological features (posi-
tive reactions to silver stains, enolase, synaptophysin, and
chromogranin), and arise from the enterocrhomaffin or
Kulchitsky cells [2].
There is no globally accepted classification for carcinoid
tumours although most series and reports are based upon
the embryologic origin of the organ and its blood supply.
Hence, they can be divided into; foregut (lungs, oesopha-
gus, stomach, liver and upper duodenum), midgut (small
intestine and proximal colon), and hindgut (distal colon
and rectum) carcinoid tumours [1-4]. Depending on their
origin, they secrete different hormones and substances.
Such reported examples include; bombesin, growth hor-
mone, adrenocorticotropin hormone, glucagons, catecho-
lamines, gastrin, insulin, and serotonin[1,4]. However,
serotonin secretion is usually associated with midgut car-
cinoids [5].
The incidence of carcinoid tumours is reported to be 0.5 –
8.4 cases per 100,000, although they have been reported
to be present in 1% of autopsies [4,6,7]. The principle site
is the gastrointestinal tract, followed by the lung and
bronchus [7]. The appendix was the most frequent site
within the GI tract, followed by the rectum and the ileum.
However, more recent data from the National Cancer
Institute Surveillance, Epidemiology, and End Results
(SEER) program (1973–1997) has quantified the preva-
lence of carcinoid in the different sites, with the majority
of carcinoid tumours occurring in the gastrointestinal
tract (54.5%), followed by the lung and bronchus (30%),
pancreas (2.3%), gynaecological/ovarian (1.2%), and the
biliary tract (1.1%). Within the gastrointestinal tract, the
small intestine (44.7%) is the most frequent site, followed
by the rectum (19.6%), appendix (16.7%), colon
(10.6%), and the stomach (7.2%) [8,9]. Within the small
intestine, the ileum is the principal site of origin, occur-
ring in greater than fifty percent of cases.
The symptoms of intestinal carcinoid tumour are non-
specific and vague, generally consisting of periodical
abdominal pain as a major symptom, along with intesti-
nal obstruction, intermittent diarrhoea, and gastrointesti-
nal bleeding [1,5,10]. Intestinal obstruction, due to a
desmoplastic reaction from the tumour causing local
mesenteric fibrosis, can lead to the need of surgery and to
the incidental finding of a carcinoid tumour [6]. The inci-
dence of carcinoid syndrome is variable, reported to occur
in 1.6–18% of cases, depending on the location of the pri-
mary tumour, local tumour extension, and the secretion
of serotonin and other amines [2,5,10,11]. Therefore, ileal
carcinoids are more likely to develop the syndrome with
almost 90% of patients with carcinoid syndrome having a
small bowel carcinoid [5]. Whilst the development of
hepatic metastasis has been a common established pre-
requisite for the development of carcinoid syndrome, it is
not essential [2,11]. Despite the fact that serotonin is
almost always present in carcinoid syndrome, the classical
symptoms of the syndrome, flushing, diarrhoea, intesti-
nal cramps, heart valves lesions, asthma and wheezing are
thought to be caused by other amines, with one example
being flushing caused by bradykinin [2,11]. Nevertheless,
as many as 40–60% of patients are asymptomatic and as
the symptoms are often non-specific, this may lead to a
delay in diagnosis with a range from 2–20 years. In one
series, the median delay for abdominal carcinoid tumours
was 5.5 years, with a maximum delay of 22 years,
although 12% had no delay [10]. At diagnosis, 10% had
only a primary tumour, 20% had lymph node metastases,
41% liver metastases, 16% carcinomatosis, and 13% had
extra-abdominal metastases. These findings correlate with
other studies [6,11].
Carcinoids are usually discovered during laparotomy for
intestinal obstruction or pain, and the existence of multi-
ple primary tumours is remarkable in 26–28% of cases
[5,12]. The evidence suggests that this multiplicity is gen-
erated by metastases from the primary tumour [13]. They
are more aggressive than other intestinal carcinoids, with
transmural invasion (77–78%), lymph node metastasis
(31–66%), and liver or mesenteric metastasis (10–32%)
[5,11,12]. This is associated with a poorer prognosis, with
adjusted five-year of 58%, as compared with 86–92% for
appendiceal tumours [9,11]. The five-year overall survival
for all carcinoid tumours varies from 70–75% for local-
ized tumours [2,8].
With hepatic metastasis, the ten-year survival is reported
to be 20%, however, recent study shows 5-year survival
between the groups with non-aggressive and aggressive
liver resection to be 25% versus 72% [6,14]. The medianWorld Journal of Surgical Oncology 2006, 4:75 http://www.wjso.com/content/4/1/75
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survival in patients with the carcinoid syndrome is 3.5–
8.5 years [5].
Peritoneal carcinomatosis from carcinoid tumours has
been scarcely reported in the form of a limited number of
case reports. Recently, in a series of 116 cases of intestinal
neuroendocrine tumours [15], thirty were carcinoids.
Within this series, the prevalence of peritoneal carcinoma-
tosis was 27% (8/30). Ileal carcinoid tumours were the
most frequent source of peritoneal carcinomatosis in 7/8
patients, and 6/8 had synchronous liver metastasis. The
five-year survival for carcinoid tumours with and without
peritoneal carcinomatosis was 65% versus 75%, although
no deaths were related to the carcinomatosis. For all the
intestinal neuroendocrine tumours within this series, the
five-year survival with or without liver metastasis was 74%
and 94 %, respectively. Again, the interval between diag-
noses from primary tumour to peritoneal carcinomatosis
was very long (overall median time 20 months, 0–273
months), and from symptoms to diagnosis was 54
months. Life expectancy was not affected by the carcino-
matosis, but it was if liver metastases were present.
In another large series of 111 endocrine carcinomas that
were surgically treated [16], 81% (30/37) were carcinoids
(the vast majority from the ileum, 83% (25/30)), with
peritoneal carcinomatosis identified in (37/111). In this
series, 17 patients with peritoneal carcinomatosis under-
went radical surgery plus intra-peritoneal chemotherapy,
with the procedures being described as palliative, but with
the aim of reducing bowel obstruction and pain. They had
no postoperative mortality, and had a morbidity rate of
47%. Five year survival was 40.9% for those in whom
complete resection was not possible, (cause of death
being from liver failure in 60% and bowel obstruction in
40%) and 66.9% for those with cytoreductive surgery plus
intraperitoneal chemotherapy (deaths from liver failure
23.5%, bowel obstruction 5.8% and cerebral haemor-
rhage 5.8%. They conclude that carcinoid carcinomatosis
is direct cause of death in 40% of cases if no specific ther-
apy is used.
In our particular reported case of peritoneal carcinomato-
sis from a carcinoid tumour, ten years passed from the ini-
tial surgery to the carcinomatosis, although the patient
related colic abdominal pain two years before the emer-
gency operation. This was probably due to the ileal carci-
noid tumour. Whilst colic is generally the principle
symptom, it was vague and did not lead to investigation
of a possible cause, and is likely the reason for the delay
in diagnosis. Radical surgery is the only potential curative
therapy and Somatostatin or analogues have been widely
used as good effectors for control of symptoms [4,5,17]
The anti-proliferate potential of Somatostatin and ana-
logues, even for reduction of metastasis, as indicated else-
where [17-19], is questionable and further evaluation is
warranted. The use of radio-labelled Somatostatin ana-
logues for advance carcinoids has been previously pub-
lished [18]. Indium-DTPA-octreotide has a low response
rate (around 10–20%), yttrium-DOTA-Tyr3-octreotide
has reported rates of complete remission in the 20–30%
range, and a more recently developed compound, lute-
tium-DOTA-Tyr3-octreotate, has a reported rate of com-
plete remission in approximately 40% of cases [19,20].
However, further investigation is needed before a consen-
sus can be reached. Furthermore, other drugs such as 5-
fluorouracil, streptozotocin, doxorubicin, leucovorin, and
interferon have been employed with different combina-
tions, but the responses have been poor [5]. The use of
intraperitoneal chemotherapy has little evidence, but the
progressive use of this method associated with extensive
cytoreductive surgery for other types of tumours (carcino-
matosis from colon adenocarcinoma, ovarian adenocarci-
noma and appendiceal mucinous cystadenoma) make
this a suitable and promising technique.
Conclusion
Radical surgery, aimed at local cure with ileal carcinoids,
is associated with a better prognosis and longer survival.
Improvements in quality of life can be achieved using
Somatostatin, but progression of the disease is predicta-
ble. The surgeon can approach these tumours with the
knowledge that carcinomatosis is more common than
expected. Survival is longer compared with adenocarci-
noma and therefore maximal efforts must be achieved to
control the disease.
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